Friday 6 November 2026 Export ORKA’s income statement to Excel — free account

Oruka Therapeutics, Inc.

ORKA Healthcare Biotechnology

EPS: −19.6%
Free cash flow: −43.0%

Quarter to June 2026, against a year earlier

102.68 6.66 +6.94%

Follow ORKA

Alert me

Market cap: $6.4B
P/E: 0.0×
Fwd P/E: —
Dividend yield: 0.00%
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Oruka Therapeutics, Inc. 10-Q filed Aug 10, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Aug 10, 2026 · accepted 4:06 PM ET · Document on sec.gov · Filing index

Red flags

Share dilution Aug 10, 2026
Shares outstanding rose 76.8% in a year, to 66.2 million

10-Q filed Aug 10, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed May 13, 2026: 12 modified